The dual-incretin molecule, read at the chemistry: how one engineered 39-residue peptide moves blood pressure, lipids and weight in the trial record.
Tirzepatide Chemical

Tirzepatide Research: Mechanism, Trials, and Cardiometabolic Evidence — Tirzepatide Chemical

The short version

Tirzepatide research has generated one of the largest and most consistent efficacy datasets in the modern incretin era: a phase 3 programme across at least eight major randomised controlled trials — SURPASS 1-5 and SURPASS-CVOT in type 2 diabetes, SURMOUNT 1-5 in obesity, SYNERGY-MASH in fatty liver disease, and SUMMIT in heart failure — totalling tens of thousands of participants. The cardiometabolic-outcomes thread runs through all of it: blood sugar down, body weight down, blood pressure down, cholesterol improved, and early readouts from the cardiovascular outcomes trial showing a lower rate of a broad cardiorenal composite versus an active comparator. This page covers the mechanistic basis and the key trial readouts, with every number cited.

Tirzepatide mechanism of action: imbalanced, biased dual agonism

The discovery paper (Coskun et al., Mol Metab, 2018) established tirzepatide as a novel fatty-acid-modified dual GIP and GLP-1 receptor agonist. In vitro, it activated both GIP and GLP-1 receptor signalling; in mice, chronic administration reduced body weight and food intake more than a selective GLP-1 receptor agonist; in a 142-subject Phase 1 human programme, it supported once-weekly dosing and showed reduced fasting glucose and body weight versus placebo [1].

The mechanistic characterisation paper (Willard et al., JCI Insight, 2020) reported that tirzepatide is an imbalanced, biased dual agonist: it engages the GIP receptor to a greater degree than the GLP-1 receptor, and at the GLP-1 receptor it exhibits biased signalling that favours cAMP generation over beta-arrestin recruitment, with weaker GLP-1 receptor internalisation than native GLP-1. In primary islet experiments, beta-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide [2]. This biased profile is proposed to maintain insulin secretion over time rather than desensitising the receptor.

A later review (Campbell et al., Cell Metab, 2023) synthesised the chemistry and physiology of GIPR/GLP-1R dual agonist therapies, providing mechanistic context for the clinical trial magnitude [32].

SURPASS programme: type 2 diabetes trials

The SURPASS trials enrolled adults with type 2 diabetes across a range of background therapies and established CV disease risk profiles.

SURPASS-2 (Frias JP, et al., N Engl J Med, 2021): 40-week open-label phase 3 trial in 1,879 adults with type 2 diabetes on metformin. Once-weekly tirzepatide 5/10/15 mg reduced HbA1c by 2.01/2.24/2.30 percentage points versus 1.86 percentage points with a selective GLP-1 comparator (superior at all doses). Body weight reduction: tirzepatide produced 1.9, 3.6, and 5.5 kg more weight reduction [3].

SURPASS-CVOT (ClinicalTrials.gov NCT04255433): the cardiovascular outcomes trial comparing tirzepatide up to 15 mg versus a GLP-1 receptor agonist 1.5 mg in adults with type 2 diabetes and established cardiovascular disease [9]. A post-hoc JAMA Cardiology analysis (Nissen SE, et al., 2026) found tirzepatide associated with a 16% lower incidence of a broad six-component cardiorenal composite endpoint (HR 0.84) [13]. GI adverse events were more common with tirzepatide (42.5% vs 35.9%) [13].

Systolic blood pressure — A Cardiovascular Diabetology pooled SURPASS-programme analysis (Kaplan LM, et al., 2023) reported clinically meaningful systolic blood-pressure reductions across the programme [8]. A seven-RCT meta-analysis (Kanbay M, et al., Diabetes Obes Metab, 2023) quantified: -4.20 mmHg (5 mg), -5.34 mmHg (10 mg), -5.77 mmHg (15 mg) systolic; LDL-cholesterol and triglycerides also fell; HDL-cholesterol rose [10].

Diabetes Care comparator analysis (Vadher K, et al., 2024): comparison of tirzepatide versus basal insulins found superior glycaemic and weight outcomes across comparator regimens [11].

Older adults (Rasouli N, et al., 2025): a pooled SURPASS analysis in older adults found tirzepatide maintained consistent glycaemic efficacy; hypoglycaemia incidence stayed consistent regardless of background insulin or sulfonylurea use [33].

SURMOUNT programme: obesity and weight management trials

SURMOUNT-1 (Jastreboff AM, et al., N Engl J Med, 2022): 72-week phase 3 RCT in 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a complication, without diabetes. Mean weight change at week 72: -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) versus -3.1% placebo. Adverse events were mostly mild-to-moderate GI events during dose escalation [4].

SURMOUNT-5 (Aronne LJ, et al., N Engl J Med, 2025): 72-week open-label head-to-head in 751 adults with obesity without diabetes. Maximum tolerated tirzepatide (10/15 mg) versus maximum tolerated selective GLP-1 comparator (1.7/2.4 mg). Weight change: tirzepatide -20.2% versus comparator -13.7% (P<0.001) [5].

SURMOUNT-4 (Aronne LJ, et al., JAMA, 2024): withdrawal design. Participants stabilised on tirzepatide then switched to placebo regained approximately 11.8% of starting body weight by week 88; those continuing on tirzepatide continued to lose [18].

Concomitant weight-inducing medications (Galindo RJ, et al., JAMA Netw Open, 2026): roughly one-fifth of SURMOUNT-1/3/4 participants used weight-inducing medications; weight change remained comparable to the overall programme results [34].

SURPASS-CN-MONO (Yin Y, et al., Med, 2026): phase 3 RCT in Chinese adults with early type 2 diabetes. HbA1c treatment differences at week 40: -2.04%, -1.93%, -2.02% (5/10/15 mg vs placebo). Consistent with the global SURPASS programme [35].

SURMOUNT-OSA (Malhotra A, et al., N Engl J Med, 2024): significant reduction in apnea-hypopnea index; formed the basis for the obstructive sleep apnea FDA indication [15].

SUMMIT (Packer M, et al., N Engl J Med, 2025): significant improvement in heart failure symptoms and physical limitations in HFpEF (heart failure with preserved ejection fraction) with obesity [16].

SYNERGY-NASH/MASH (Loomba R, et al., N Engl J Med, 2024): significant improvements in histological endpoints (fibrosis and steatohepatitis) in metabolic dysfunction-associated steatohepatitis with liver fibrosis [12].

Tirzepatide vs semaglutide: the head-to-head evidence

Three streams of evidence now address tirzepatide vs semaglutide.

Head-to-head RCTs: SURPASS-2 in type 2 diabetes established superiority on HbA1c and body weight versus semaglutide 1 mg [3]. SURMOUNT-5 established superiority on body weight versus semaglutide 2.4 mg in obesity without diabetes [5].

Observational data: Krüger N, et al. (Nat Med, 2026) analysed five US insurance-programme cohort studies (2018-2025) with propensity-score matching; for MI/stroke/all-cause mortality, tirzepatide versus dulaglutide HR 0.87 (95% CI 0.75-1.01); semaglutide versus sitagliptin HR 0.82 (0.74-0.91) for MI or stroke; head-to-head tirzepatide versus semaglutide HR 1.06 (95% CI 0.95-1.18) — not statistically different for the cardiovascular outcomes composite [14].

The glycaemic and weight advantage of dual-receptor agonism versus selective GLP-1 receptor agonism is well-established in the phase 3 programme; the cardiovascular outcomes advantage in direct comparison remains an active research question.

Cardiovascular and cardiorenal evidence: the cardiometabolic-outcomes lens

The cardiometabolic-outcomes thread is increasingly the central research frontier for tirzepatide beyond glycaemia and weight.

The SURPASS-CVOT registry (NCT04255433) is the dedicated cardiovascular outcomes trial, designed to assess MACE (major adverse cardiovascular events) versus a GLP-1 receptor agonist in type 2 diabetes with established cardiovascular disease [9]. The JAMA Cardiology post-hoc analysis (Nissen SE, et al., 2026) found a 16% lower incidence of a six-component cardiorenal composite (HR 0.84) [13].

The Krüger Nat Med 2026 real-world analysis provides an independent observational read, finding broadly comparable cardiovascular outcomes between tirzepatide and semaglutide in clinical practice [14].

Mechanistically, the blood-pressure and lipid panel improvements documented in the Kanbay meta-analysis [10] and the Kaplan SURPASS pooled analysis [8] are independently cardiometabolic signals — not just consequences of weight reduction. Whether GIPR agonism contributes directly to cardiometabolic benefit beyond what GLP-1R agonism alone provides is an active area of investigation.